2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
    Neuronal Signaling
  4. Calcium Channel
  5. T-type calcium channel Isoform

T-type calcium channel

 

T-type calcium channel Related Products (24):

Cat. No. Product Name Effect Purity
  • HY-B0166
    L-Ascorbic acid
    		Inhibitor 99.96%
    L-Ascorbic acid (L-Ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid inhibits selectively Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid is also a collagen deposition enhancer and an elastogenesis inhibitor. L-Ascorbic acid exhibits anti-cancer effects through the generation of reactive oxygen species (ROS) and selective damage to cancer cells.
  • HY-B0166A
    L-Ascorbic acid sodium salt
    		Inhibitor 99.97%
    L-Ascorbic acid sodium salt (Sodium ascorbate), an electron donor, is an endogenous antioxidant agent. L-Ascorbic acid sodium salt selectively inhibits Cav3.2 channels with an IC50 of 6.5 μM. L-Ascorbic acid sodium salt is also a collagen deposition enhancer and an elastogenesis inhibitor.
  • HY-15553A
    Mibefradil dihydrochloride
    		Inhibitor ≥98.0%
    Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels (IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively).
  • HY-B0358A
    Flunarizine dihydrochloride
    		Inhibitor 99.87%
    Flunarizine dihydrochloride is a potent dual Na+/Ca2+ channel (T-type) blocker. Flunarizine dihydrochloride is a D2 dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects.
  • HY-50722
    NNC 55-0396
    		Inhibitor ≥99.0%
    NNC 55-0396 is a highly selective T-type calcium channel blocker with an IC50 value of 6.8 μM for Cav3.1 T-type channels. NNC 55-0396 can be used for the research of neurological disease research.
  • HY-161076
    KTt-45
    KTt-45 is a T-type calcium channel blocker. KTt-45 has anticancer effect by inducing apoptosis on HeLa cervical cancer cell line.
  • HY-17403
    Manidipine dihydrochloride
    		Inhibitor 99.91%
    Manidipine dihydrochloride is a third-generation, lipophilic, orally active and highly vasoselective calcium channel antagonist (IC50 = 2.6 nM in guinea-pig ventricular cells) and acts as an antihypertensive agent. Manidipine effectively reduces blood pressure as well as improving insulin sensitivity, renal protection, and antiatherosclerotic activity. Manidipine also exerts anti-inflammatory activity mediated by NF-κB and antiviral activity against many flavivirus and negative-strand RNA viruses through the inhibition of calcium channel. Manidipine is widely applied to research of cardiovascular, metabolic disease and infection.
  • HY-B1378
    Ethosuximide
    		Inhibitor 99.26%
    Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel.
  • HY-120546
    Ulixacaltamide
    		Antagonist 99.72%
    Ulixacaltamide (Z944) is an orally active T-type calcium channel antagonist that rescues impairments in crossmodal and visual recognition memory.
  • HY-B0768A
    Lomerizine dihydrochloride
    		Antagonist 99.84%
    Lomerizine dihydrochloride is an antagonist of L- and T-type voltagegated calcium channels.
  • HY-19721
    ABT-639
    		Inhibitor 99.32%
    ABT-639 is a novel, peripherally acting, selective T-type Ca2+ channel blocker.
  • HY-101096
    Suvecaltamide
    		Inhibitor 99.80%
    Suvecaltamide (MK-8998; compound 33) is a potent and selective inhibitor of the T-type calcium channel.
  • HY-A0092
    Trimethadione
    		Inhibitor ≥98.0%
    Trimethadione (3,5,5,-Trimethyloxazolidine-2,4-dione) is an oxazolidinedione anticonvulsant agent widely used against absences seizures. Trimethadione also is a T-type calcium channel blocker which has antihyperalgesic effects.
  • HY-112723
    Apinocaltamide
    		Antagonist 99.59%
    Apinocaltamide (ACT-709478) is a potent, selective, orally active, and brain penetrating T-type calcium channel blocker. ACT-709478 is used in the research of generalized epilepsies.
  • HY-W011235
    Norfluoxetine hydrochloride
    		Inhibitor 99.27%
    Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). Norfluoxetine hydrochloride has anticonvulsant activity.
  • HY-W032013
    1-Octanol
    		Inhibitor ≥98.0%
    1-Octanol (Octanol), a saturated fatty alcohol, is a T-type calcium channels (T-channels) inhibitor with an IC50 of 4 μM for native T-currents. 1-Octanol is a highly attractive biofuel with diesel-like properties.
  • HY-115681
    (2R/S)-6-PNG
    		Inhibitor 99.88%
    (2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Cav3.2 T-type Ca2+ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice.
  • HY-10388A
    TTA-Q6(isomer)
    		99.84%
    TTA-Q6(isomer) is an isomer of TTA-Q6. TTA-Q6 is a selective T-type Ca2+ channel antagonist.
  • HY-150541
    IAA65
    		Inhibitor
    IAA65 is a potent T-type calcium channel inhibitor with a IC50 value of 18.9 µM. IAA65 can be used for epilepsy research.
  • HY-150539
    IAB15
    		Inhibitor
    IAB15 is a potent T-type calcium channel inhibitor. IAB15 can be used for epilepsy research.